Ivabradin Aristo (Ivabradine)

Ivabradine acts on the cardiac If current to lower heart rate, benefiting conditions where heart‑rate control improves outcomes.

• Chronic stable angina pectoris: reduces the frequency of angina attacks by lowering myocardial oxygen demand.
• Heart failure with reduced ejection fraction (NYHA class II–III): improves exercise capacity and lowers risk of hospitalization.
• Elevated resting heart rate despite optimal therapy: provides additional heart‑rate reduction when beta‑blockers are insufficient or not tolerated.

• Ivabradine selectively inhibits the funny (If) current in the sino‑atrial node, which slows depolarisation of pacemaker cells. This results in a dose‑dependent reduction in heart rate without affecting myocardial contractility or systemic blood pressure, thereby decreasing cardiac workload and oxygen consumption.

Ivabradine is generally well tolerated, but several adverse reactions have been reported.

Common Side Effects

• Bradycardia: resting heart rate falls below the intended range.
• Visual disturbances (phosphenes): transient luminous phenomena.
• Headache: mild to moderate intensity.
• Dizziness or vertigo.
• Fatigue or general weakness.
• Nausea.

Serious or Rare Side Effects

• Symptomatic severe bradycardia requiring medical intervention.
• Atrial fibrillation or other supraventricular arrhythmias.
• Persistent visual impairment or retinal changes.
• Myocardial ischemia due to excessive heart‑rate reduction.
• Allergic reactions such as rash or angioedema.

Before initiating ivabradine, clinicians should assess patient suitability and monitor for specific risks.

• Heart‑rate monitoring: ensure resting HR ≥60 bpm before starting.
• Conduction disorders: avoid in patients with sick sinus syndrome or second‑degree AV block.
• Hepatic impairment: use caution and consider dose adjustment in severe liver disease.
• CYP3A4 inhibitors: avoid strong inhibitors that may raise ivabradine levels.
• Pregnancy and lactation: only use if potential benefit justifies potential risk.
• Store at ambient temperature: keep in the original pack, protect from moisture and light.

Ivabradine may interact with several drug classes, requiring attention to avoid adverse outcomes.

Major Interactions (Avoid)

• Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin): can markedly increase plasma concentrations.
• Concomitant bradycardic agents (beta‑blockers, digoxin, verapamil): may cause severe bradycardia.
• Other If channel inhibitors: additive heart‑rate lowering effect.

Moderate Interactions (Monitor Closely)

• Moderate CYP3A4 inhibitors (diltiazem, erythromycin): may require dose adjustment.
• CYP3A4 inducers (rifampicin, carbamazepine): may reduce efficacy.
• Antihypertensives: monitor blood pressure and heart rate.
• Diuretics: watch for electrolyte disturbances that could affect cardiac conduction.